Conference
A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a
Abstract
BACKGROUND: The purpose of this study was to determine the clinical activity of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.
PATIENTS AND METHODS: Eligible patients had progressive disease within 6 months of receiving docetaxel. Patupilone was administered 10 mg/m2 i.v. every 3 weeks. The primary end point was the proportion of patients with a confirmed≥50% prostate-specific …
Authors
Chi KN; Beardsley E; Eigl BJ; Venner P; Hotte SJ; Winquist E; Ko Y-J; Sridhar SS; Weber D; Saad F
Volume
23
Pagination
pp. 53-58
Publisher
Elsevier
Publication Date
January 2012
DOI
10.1093/annonc/mdr336
Conference proceedings
Annals of Oncology
Issue
1
ISSN
0923-7534